We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

90 hedge funds and large institutions have $16.5M invested in Akebia Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

521% more call options, than puts

Call options by funds: $292K | Put options by funds: $47K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.94% less ownership

Funds ownership: 31.33% → 28.39% (-2.9%)

6% less funds holding

Funds holding: 96 → 90 (-6)

18% less capital invested

Capital invested by funds: $20.2M → $16.5M (-$3.69M)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

47% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 32

Holders
90
Holders Change
-6
Holders Change %
-6.25%
% of All Funds
1.55%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
17
Reduced
32
Closed
16
Calls
$292K
Puts
$47K
Net Calls
+$245K
Net Calls Change
+$98K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$602K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$496K
3
GCP
GSA Capital Partners
United Kingdom
+$191K
4
Two Sigma Investments
Two Sigma Investments
New York
+$127K
5
Marshall Wace
Marshall Wace
United Kingdom
+$123K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.21M
2
Millennium Management
Millennium Management
New York
-$735K
3
HF
HRT Financial
New York
-$424K
4
AQR Capital Management
AQR Capital Management
Connecticut
-$304K
5
E
Ergoteles
New York
-$268K
Name Holding Trade Value Shares
Change 		Change in
Stake
Rockefeller Capital Management
76
Rockefeller Capital Management
New York
$1K – – –
CUAMC
77
China Universal Asset Management Company
China
$1K +$675 +1,721 New
CG
78
Cutler Group
California
$1K +$1.26K +3,200 +1,600%
TWC
79
TD Waterhouse Canada
Ontario, Canada
$633 – – –
FDCDDQ
80
Federation des caisses Desjardins du Quebec
Quebec, Canada
$47 – – –
AQR Capital Management
81
AQR Capital Management
Connecticut
– -$304K -862,168 Closed
VOYA Investment Management
82
VOYA Investment Management
Georgia
– -$107K -301,740 Closed
PAM
83
Panagora Asset Management
Massachusetts
– -$89K -250,894 Closed
Parallax Volatility Advisers
84
Parallax Volatility Advisers
California
– -$39K -109,683 Closed
BCI
85
Brinker Capital Investments
Pennsylvania
– -$11K -30,196 Closed
Squarepoint
86
Squarepoint
New York
– -$10K -29,471 Closed
Teacher Retirement System of Texas
87
Teacher Retirement System of Texas
Texas
– -$9K -25,737 Closed
YIH
88
Y-Intercept (HK)
Hong Kong
– -$9K -25,303 Closed
PAG
89
Private Advisor Group
New Jersey
– -$7K -20,316 Closed
CSS
90
Cubist Systematic Strategies
Connecticut
– -$6K -18,295 Closed
Legal & General Group
91
Legal & General Group
United Kingdom
– -$5K -13,943 Closed
CC
92
Centiva Capital
New York
– -$5K -13,638 Closed
RJA
93
Raymond James & Associates
Florida
– -$5K -12,900 Closed
Verition Fund Management
94
Verition Fund Management
Connecticut
– -$4K -10,673 Closed
New York State Common Retirement Fund
95
New York State Common Retirement Fund
New York
– -$1K -1,595 Closed
TC
96
Truvestments Capital
Florida
– -$57 -144 -16%
Royal Bank of Canada
97
Royal Bank of Canada
Ontario, Canada
– -$47 -120 -20%
1 2 3
4

AKBA Hedge Fund Activity: Q3 2022 in Review

90 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2022, worth a combined $16.5M — down 18% from $20.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AKBA and 12 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 17 added.

The largest buyer was Renaissance Technologies, adding an estimated $602K. The largest seller was Vanguard Group, cutting an estimated $1.21M.

  • 90 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2022, down from 96 in Q2 2022.
  • Funds reported $16.5M of Akebia Therapeutics stock for Q3 2022, down 18% quarter-over-quarter.
  • 12 funds opened new Akebia Therapeutics positions in Q3 2022 and 16 closed out, a net change of -4 holders.
  • The largest Akebia Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $602K added.
  • The largest Akebia Therapeutics seller in Q3 2022 was Vanguard Group, an estimated $1.21M sold.

Based on aggregated 13F filings for Q3 2022.